Anadol E, Beckebaum S, Radecke K, Paul A, Zoufaly A, Bickel M, Hitzenbichler F, Ganten T, Kittner J, Stoll M, Berg C, Manekeller S, Kalff J C, Sauerbruch T, Rockstroh J K, Spengler U
Department of Internal Medicine I, University of Bonn, 53105 Bonn, Germany.
AIDS Res Treat. 2012;2012:197501. doi: 10.1155/2012/197501. Epub 2012 Jul 30.
Objectives. This summary evaluates the outcomes of orthotopic liver transplantation (OLT) of HIV-positive patients in Germany. Methods. Retrospective chart analysis of HIV-positive patients, who had been liver-transplanted in Germany between July 1997 and July 2011. Results. 38 transplantations were performed in 32 patients at 9 German transplant centres. The reasons for OLT were end-stage liver disease (ESLD) and/or liver failure due to hepatitis C (HCV) (n = 19), hepatitis B (HBV) (n = 10), multiple viral infections of the liver (n = 2) and Budd-Chiari-Syndrome. In July 2011 19/32 (60%) of the transplanted patients were still alive with a median survival of 61 months (IQR (interquartile range): 41-86 months). 6 patients had died in the early post-transplantation period from septicaemia (n = 4), primary graft dysfunction (n = 1), and intrathoracal hemorrhage (n = 1). Later on 7 patients had died from septicaemia (n = 2), delayed graft failure (n = 2), recurrent HCC (n = 2), and renal failure (n = 1). Recurrent HBV infection was efficiently prevented in 11/12 patients; HCV reinfection occurred in all patients and contributed considerably to the overall mortality. Conclusions. Overall OLT is a feasible approach in HIV-infected patients with acceptable survival rates in Germany. Reinfection with HCV still remains a major clinical challenge in HIV/HCV coinfection after OLT.
目的。本综述评估了德国HIV阳性患者原位肝移植(OLT)的结果。方法。对1997年7月至2011年7月间在德国接受肝移植的HIV阳性患者进行回顾性病历分析。结果。德国9个移植中心为32例患者实施了38例移植手术。OLT的原因包括终末期肝病(ESLD)和/或丙型肝炎(HCV)导致的肝衰竭(n = 19)、乙型肝炎(HBV)(n = 10)、肝脏多重病毒感染(n = 2)以及布加综合征。到2011年7月,19/32(60%)的移植患者仍然存活,中位生存期为61个月(四分位间距(IQR):41 - 86个月)。6例患者在移植后早期死于败血症(n = 4)、原发性移植物功能障碍(n = 1)和胸腔内出血(n = 1)。后来有7例患者死于败血症(n = 2)、移植肝功能延迟衰竭(n = 2)、复发性肝癌(n = 2)和肾衰竭(n = 1)。11/12例患者的HBV再感染得到有效预防;所有患者均发生HCV再感染,且对总体死亡率有很大影响。结论。总体而言,在德国,OLT对于HIV感染患者是一种可行的方法,生存率可接受。OLT后HIV/HCV合并感染中,HCV再感染仍然是一个主要的临床挑战。